ASPARLAS
Total Payments
$4.8M
Transactions
1,009
Doctors
335
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $3.0M | 762 | 267 |
| 2021 | $1.1M | 103 | 66 |
| 2020 | $261,965 | 121 | 28 |
| 2019 | $377,158 | 23 | 14 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 59 | 91.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $234,330 | 76 | 4.9% |
| Consulting Fee | $112,429 | 25 | 2.4% |
| Travel and Lodging | $43,127 | 243 | 0.9% |
| Food and Beverage | $31,420 | 590 | 0.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,920 | 5 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $1,500 | 1 | 0.0% |
| Education | $211.30 | 10 | 0.0% |
Payments by Type
Research
$4.4M
59 transactions
General
$427,937
950 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CALASPARGASE PEGOL IN ADULTS WITH ALL | Servier BioInnovation | $2.2M | 0 |
| CALASPARGASE PEGOL IN ADULTS WITH ALL | Institut de Recherches Servier | $777,728 | 0 |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell LeukemiaLymphoma | Servier Pharmaceuticals LLC | $376,334 | 0 |
| Asparlas combined with BCL2 in in relapsed/refractory AML in a murine model (S65487) | Servier BioInnovation | $246,127 | 0 |
| A STUDY ON DRUG MONITORING OF ASPARAGINASE ACTIVITY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA | Servier Pharmaceuticals LLC | $170,727 | 0 |
| Preventing ASNase-associated pancreatitis using the novel dimension of metabolomics and proteomics | Servier Pharmaceuticals LLC | $163,600 | 0 |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Servier BioInnovation | $125,000 | 0 |
| A Phase 1 Study of Venetoclax in Combination with Vincristine, Doxorubicin, Dexamethasone, and Calaspargase (VEN-VDDC) in Children, Adolescents, and Young Adults with relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma | Servier BioInnovation | $82,250 | 0 |
| Asparaginase Premedication, Hypersensitivity, and Therapeutic Drug Monitoring in Pediatric Patients with Acute Lymphoblastic Leukemia or Lymphoma | Servier Pharmaceuticals LLC | $76,175 | 0 |
| ASPARLAS COMBINED WITH MCL1 INHIBITOR IN AML IN A MURINE MODEL (S64315) | Servier BioInnovation | $63,607 | 0 |
| Treatment of Newly Diagnosed Acute LymphoblasticLeukemiain Children and Adolescents | Servier Pharmaceuticals LLC | $42,682 | 0 |
Top Doctors Receiving Payments for ASPARLAS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Valhalla, NY | $4.4M | 62 |
| , MD | Pediatric Hematology-Oncology | Hawthorne, NY | $122,572 | 184 |
| , M.D | Hematology | New York, NY | $42,704 | 35 |
| , MD | Pediatric Hematology-Oncology | Seattle, WA | $29,540 | 68 |
| , M.D | Pediatric Hematology-Oncology | Hartford, CT | $23,294 | 20 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $19,802 | 21 |
| , MD | Pediatrics | Charlotte, NC | $19,658 | 26 |
| , DO | Obstetrics & Gynecology | Charlotte, NC | $16,065 | 8 |
| , MD | Hematology & Oncology | New York, NY | $14,125 | 15 |
| Wendy Stock | Hematology & Oncology | Burr Ridge, IL | $11,273 | 11 |
| , RN CNP | Nurse Practitioner | Woodbury, MN | $6,681 | 11 |
| , M.D | Hematology | Duarte, CA | $6,105 | 12 |
| , M.D | Internal Medicine | Chicago, IL | $4,773 | 11 |
| , MD | Internal Medicine | New York, NY | $4,768 | 8 |
| , MD | Hematology & Oncology | Cincinnati, OH | $4,740 | 9 |
| , MD | Hematology & Oncology | Jacksonville, FL | $4,659 | 11 |
| , MD, PHD | Internal Medicine | Baltimore, MD | $4,622 | 12 |
| , M.D | Medical Oncology | Baltimore, MD | $4,535 | 11 |
| , M.D.,PH.D | Hematology & Oncology | Boston, MA | $3,890 | 7 |
| , MD | Pediatric Hematology-Oncology | Washington, DC | $3,311 | 3 |
| , MD | Pediatrics | Boston, MA | $2,894 | 4 |
| , M.D | Pediatrics | Memphis, TN | $2,720 | 1 |
| , MD | Pediatric Hematology-Oncology | Houston, TX | $2,720 | 1 |
| , MD | Pediatric Hematology-Oncology | Memphis, TN | $2,720 | 1 |
| , M.D | Internal Medicine | Cambridge, MA | $2,640 | 1 |
Ad
Manufacturing Companies
- Servier BioInnovation $2.7M
- Servier Pharmaceuticals LLC $1.0M
- Institut de Recherches Servier $777,728
- SERVIER PHARMACEUTICALS LLC $230,535
- Institut de Recherches Internationales Servier $2,640
Product Information
- Type Drug
- Total Payments $4.8M
- Total Doctors 335
- Transactions 1,009
About ASPARLAS
ASPARLAS is a drug associated with $4.8M in payments to 335 healthcare providers, recorded across 1,009 transactions in the CMS Open Payments database. The primary manufacturer is Servier BioInnovation.
Payment data is available from 2019 to 2022. In 2022, $3.0M was paid across 762 transactions to 267 doctors.
The most common payment nature for ASPARLAS is "Unspecified" ($4.4M, 91.0% of total).
ASPARLAS is associated with 11 research studies, including "CALASPARGASE PEGOL IN ADULTS WITH ALL" ($2.2M).